STOCK TITAN

[Form 4] PERRIGO COMPANY PLC Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Geoffrey M. Parker, a director of Perrigo Company plc (PRGO), purchased 4,375 ordinary shares on 08/18/2025 at $22.9708 per share. Following the purchase, Mr. Parker is reported to beneficially own 33,287 shares directly and holds additional indirect holdings of 25,879 shares through a revocable trust and 5,500 shares in a Roth IRA, as disclosed on Form 4. The filing was signed by an attorney-in-fact on 08/19/2025 and includes explanatory notes identifying the trust and the Roth IRA as the vehicles for indirect ownership.

Geoffrey M. Parker, amministratore di Perrigo Company plc (PRGO), ha acquistato 4.375 azioni ordinarie il 18/08/2025 al prezzo di $22,9708 per azione. Dopo l’acquisto, risulta che il sig. Parker possiede direttamente 33.287 azioni e detiene ulteriori partecipazioni indirette pari a 25.879 azioni tramite un trust revocabile e 5.500 azioni in un Roth IRA, come dichiarato nel Modulo 4. La comunicazione è stata firmata da un procuratore il 19/08/2025 e include note esplicative che identificano il trust e il Roth IRA come veicoli di proprietà indiretta.

Geoffrey M. Parker, director de Perrigo Company plc (PRGO), compró 4.375 acciones ordinarias el 18/08/2025 a $22,9708 por acción. Tras la adquisición, se informa que el Sr. Parker posee directamente 33.287 acciones y mantiene participaciones indirectas adicionales de 25.879 acciones a través de un fideicomiso revocable y 5.500 acciones en un Roth IRA, según consta en el Formulario 4. La presentación fue firmada por un apoderado el 19/08/2025 e incluye notas explicativas que identifican el fideicomiso y el Roth IRA como vehículos de propiedad indirecta.

Perrigo Company plc(PRGO) 이사 Geoffrey M. Parker는 2025년 8월 18일 보통주 4,375주를 주당 $22.9708에 매수했습니다. 매수 후 Parker 씨는 직접 소유주식 33,287주를 보유하고 있으며, 취소 가능한 신탁을 통한 간접 소유 25,879주와 Roth IRA에 보관된 5,500주 등 추가 간접 보유분을 보유하고 있는 것으로 Form 4에 보고되었습니다. 해당 서류는 2025년 8월 19일 대리인이 서명했으며, 간접 소유 수단으로 신탁과 Roth IRA를 명시한 설명 노트가 포함되어 있습니다.

Geoffrey M. Parker, administrateur de Perrigo Company plc (PRGO), a acheté 4 375 actions ordinaires le 18/08/2025 au prix de 22,9708 $ par action. Après l’achat, M. Parker détiendrait directement 33 287 actions et possède en outre des participations indirectes de 25 879 actions via un trust révocable et de 5 500 actions dans un Roth IRA, comme indiqué sur le formulaire 4. Le dépôt a été signé par un mandataire le 19/08/2025 et comprend des notes explicatives identifiant le trust et le Roth IRA comme véhicules de propriété indirecte.

Geoffrey M. Parker, Direktor von Perrigo Company plc (PRGO), erwarb am 18.08.2025 4.375 Stammaktien zum Preis von $22,9708 je Aktie. Nach dem Kauf wird berichtet, dass Herr Parker direkt 33.287 Aktien besitzt und zusätzlich indirekte Beteiligungen von 25.879 Aktien über einen widerruflichen Trust sowie 5.500 Aktien in einem Roth-IRA hält, wie im Formular 4 angegeben. Die Einreichung wurde am 19.08.2025 von einem Bevollmächtigten unterzeichnet und enthält erläuternde Hinweise, die den Trust und das Roth-IRA als Vehikel der indirekten Eigentümerschaft benennen.

Positive
  • Director purchase disclosed: Geoffrey M. Parker acquired 4,375 shares at $22.9708, indicating insider buying activity.
  • Clear ownership breakdown: Filing specifies direct ownership (33,287 shares) and indirect holdings via revocable trust (25,879) and Roth IRA (5,500).
  • Proper disclosure and signature: Form 4 includes explanatory notes and a dated signature by an attorney-in-fact.
Negative
  • None.

Insights

TL;DR: Director purchased 4,375 shares at $22.97, modest insider buying with limited immediate market impact.

The reported purchase is a straightforward open-market acquisition by a director rather than part of a 10b5-1 plan, indicated by transaction code "P." The price of $22.9708 and the size—4,375 shares—result in a direct holding of 33,287 shares post-transaction. For a company-level materiality assessment, the filing provides no company market-cap or percent-change context, so this should be viewed as a routine insider purchase that may signal confidence but is not necessarily material by itself.

TL;DR: Governance disclosure is complete and includes trustee and IRA details; signature by attorney-in-fact is properly noted.

The Form 4 distinctly identifies the reporting person as a director and discloses both direct and indirect holdings, including a revocable trust and a Roth IRA, satisfying reporting detail requirements. The signature line shows filing by an attorney-in-fact, with the execution date provided. No amendments or plan-related checkboxes are marked, and the explanation clarifies the nature of indirect ownership, supporting transparency in insider disclosure.

Geoffrey M. Parker, amministratore di Perrigo Company plc (PRGO), ha acquistato 4.375 azioni ordinarie il 18/08/2025 al prezzo di $22,9708 per azione. Dopo l’acquisto, risulta che il sig. Parker possiede direttamente 33.287 azioni e detiene ulteriori partecipazioni indirette pari a 25.879 azioni tramite un trust revocabile e 5.500 azioni in un Roth IRA, come dichiarato nel Modulo 4. La comunicazione è stata firmata da un procuratore il 19/08/2025 e include note esplicative che identificano il trust e il Roth IRA come veicoli di proprietà indiretta.

Geoffrey M. Parker, director de Perrigo Company plc (PRGO), compró 4.375 acciones ordinarias el 18/08/2025 a $22,9708 por acción. Tras la adquisición, se informa que el Sr. Parker posee directamente 33.287 acciones y mantiene participaciones indirectas adicionales de 25.879 acciones a través de un fideicomiso revocable y 5.500 acciones en un Roth IRA, según consta en el Formulario 4. La presentación fue firmada por un apoderado el 19/08/2025 e incluye notas explicativas que identifican el fideicomiso y el Roth IRA como vehículos de propiedad indirecta.

Perrigo Company plc(PRGO) 이사 Geoffrey M. Parker는 2025년 8월 18일 보통주 4,375주를 주당 $22.9708에 매수했습니다. 매수 후 Parker 씨는 직접 소유주식 33,287주를 보유하고 있으며, 취소 가능한 신탁을 통한 간접 소유 25,879주와 Roth IRA에 보관된 5,500주 등 추가 간접 보유분을 보유하고 있는 것으로 Form 4에 보고되었습니다. 해당 서류는 2025년 8월 19일 대리인이 서명했으며, 간접 소유 수단으로 신탁과 Roth IRA를 명시한 설명 노트가 포함되어 있습니다.

Geoffrey M. Parker, administrateur de Perrigo Company plc (PRGO), a acheté 4 375 actions ordinaires le 18/08/2025 au prix de 22,9708 $ par action. Après l’achat, M. Parker détiendrait directement 33 287 actions et possède en outre des participations indirectes de 25 879 actions via un trust révocable et de 5 500 actions dans un Roth IRA, comme indiqué sur le formulaire 4. Le dépôt a été signé par un mandataire le 19/08/2025 et comprend des notes explicatives identifiant le trust et le Roth IRA comme véhicules de propriété indirecte.

Geoffrey M. Parker, Direktor von Perrigo Company plc (PRGO), erwarb am 18.08.2025 4.375 Stammaktien zum Preis von $22,9708 je Aktie. Nach dem Kauf wird berichtet, dass Herr Parker direkt 33.287 Aktien besitzt und zusätzlich indirekte Beteiligungen von 25.879 Aktien über einen widerruflichen Trust sowie 5.500 Aktien in einem Roth-IRA hält, wie im Formular 4 angegeben. Die Einreichung wurde am 19.08.2025 von einem Bevollmächtigten unterzeichnet und enthält erläuternde Hinweise, die den Trust und das Roth-IRA als Vehikel der indirekten Eigentümerschaft benennen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Parker Geoffrey M.

(Last) (First) (Middle)
C/O PERRIGO COMPANY PLC
515 EASTERN AVENUE

(Street)
ALLEGAN MI 49010

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PERRIGO Co plc [ PRGO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 08/18/2025 P 4,375 A $22.9708 33,287 D
Ordinary Shares 25,879 I Revocable Trust(1)
Ordinary Shares 5,500 I IRA(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Revocable trust in which Geoffrey Parker and Jill Parker are the trustees.
2. Geoffrey M. Parker Roth IRA.
Remarks:
/s/ Diana Witt, attorney-in-fact for Mr. Geoffrey Parker 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PRGO director Geoffrey M. Parker report?

The Form 4 reports a purchase of 4,375 ordinary shares on 08/18/2025 at a price of $22.9708 per share.

How many PRGO shares does Geoffrey M. Parker beneficially own after the transaction?

The filing shows 33,287 shares directly after the reported purchase, plus 25,879 shares indirectly via a revocable trust and 5,500 shares in a Roth IRA.

Was this Form 4 filed individually or jointly for PRGO?

The form indicates it was filed by one reporting person (the director Geoffrey M. Parker).

How is the indirect ownership of Geoffrey M. Parker structured?

The filing explains the indirect holdings as a revocable trust (Geoffrey and Jill Parker as trustees) and a Roth IRA for Geoffrey M. Parker.

Who signed the Form 4 for Geoffrey M. Parker and when?

The Form 4 was signed by Diana Witt, attorney-in-fact for Mr. Geoffrey Parker on 08/19/2025.
Perrigo Co Plc

NYSE:PRGO

PRGO Rankings

PRGO Latest News

PRGO Latest SEC Filings

PRGO Stock Data

3.17B
136.98M
0.4%
105.77%
4.14%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Ireland
DUBLIN 2